196695-49-5

Basic information

• Product Name: (S)-[1-((4-Benzyloxy-benzyl)-{[(1-phenyl-cyclobutylmethyl)-carbamoyl]-methyl}-carbamoyl)-2-(1H-imidazol-4-yl)-ethyl]-carbamic acid benzyl ester
• Synonyms: (S)-[1-((4-Benzyloxy-benzyl)-{[(1-phenyl-cyclobutylmethyl)-carbamoyl]-methyl}-carbamoyl)-2-(1H-imidazol-4-yl)-ethyl]-carbamic acid benzyl ester
• CAS NO: 196695-49-5
• Molecular Weight: 685.823
• Mol File: 196695-49-5.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: (S)-[1-((4-Benzyloxy-benzyl)-{[(1-phenyl-cyclobutylmethyl)-carbamoyl]-methyl}-carbamoyl)-2-(1H-imidazol-4-yl)-ethyl]-carbamic acid benzyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: (S)-[1-((4-Benzyloxy-benzyl)-{[(1-phenyl-cyclobutylmethyl)-carbamoyl]-methyl}-carbamoyl)-2-(1H-imidazol-4-yl)-ethyl]-carbamic acid benzyl ester(196695-49-5)
• EPA Substance Registry System: (S)-[1-((4-Benzyloxy-benzyl)-{[(1-phenyl-cyclobutylmethyl)-carbamoyl]-methyl}-carbamoyl)-2-(1H-imidazol-4-yl)-ethyl]-carbamic acid benzyl ester(196695-49-5)

Safety Data

• Hazardous Substances Data: 196695-49-5(Hazardous Substances Data)

Upstream product

• 196695-32-6 {(4-Benzyloxy-benzyl)-[(S)-2-benzyloxycarbonylamino-3-(1-trityl-1H-imidazol-4-yl)-propionyl]-amino}-acetic acid methyl ester 
• 196695-33-7 (S)-{(4-benzyloxy-benzyl)-[2-benzyloxycarbonylamino-3-(1-trityl-1H-imidazol-4-yl)-propionyl]-amino}-acetic acid 
• 175708-57-3 [(4-benzyloxy-benzyl)-amino]-acetic acid methyl ester 
• 4397-53-9 p-benzyloxybenzaldehyde 
• 209907-10-8 [(S)-1-((4-Benzyloxy-benzyl)-{[(1-phenyl-cyclobutylmethyl)-carbamoyl]-methyl}-carbamoyl)-2-(1-trityl-1H-imidazol-4-yl)-ethyl]-carbamic acid benzyl ester 

Relevant articles and documents

Combinations of protein farnesyltransferase and HMG CoA reductase inhibitors and their use to treat cancer

Novel combinations of inhibitors of protein farnesyltransferase enzymes and HMG CoA reductases enzymes are described, as well as methods for the preparation and pharmaceutical compositions of the same, which are useful in preventing or treating cancer, restenosis, psoriasis, endometriosis, atherosclerosis, or viral infections.

C-terminal modifications of histidyl-N-benzylglycinamides to give improved inhibition of Ras farnesyltransferase, cellular activity, and anticancer activity in mice.

-